Lebrikizumab Therapeutic Cheat Sheet
Lebrikizumab is a humanized immunoglobulin G4 (IgG4) monoclonal antibody that selectively targets IL-13, a key cytokine implicated in the pathogenesis of type 2 inflammatory diseases.1 Lebrikizumab binds IL-13 with high affinity and a slow dissociation rate, which prevents heterodimerization of the IL-13 receptor alpha-1 subunit (IL-13Rα1) with the IL-4 receptor alpha (IL-4Rα) signaling complex. …
Lebrikizumab is a humanized immunoglobulin G4 (IgG4) monoclonal antibody that selectively targets IL-13, a key cytokine implicated in the pathogenesis of type 2 inflammatory diseases.1 Lebrikizumab binds IL-13 with high affinity and a slow dissociation rate, which prevents heterodimerization of the IL-13 receptor alpha-1 subunit (IL-13Rα1) with the IL-4 receptor alpha (IL-4Rα) signaling complex. … 
The April issue of the Journal of Drugs in Dermatology features the perfect mix of medical, aesthetic, and surgical dermatology articles on topics ranging from COVID-19 Vaccines and Soft Tissue Filler Reactions to Biologic Therapy for Psoriasis. Straight from the JDD Editor’s desk, we share this month’s issue highlights:
A survey was designed to capture the incidence of adverse events in G … 
Have you received your August issue of the JDD yet? This month's issue contains a special focus on Psoriasis, as August is Psoriasis Awareness Month! Below are the issue highlights and Editor Picks for the August issue of JDD!
In Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years, high levels of effi …